Home » Stocks » HSDT

Helius Medical Technologies, Inc. (HSDT)

Stock Price: $14.49 USD -0.57 (-3.75%)
Updated May 13, 2021 3:59 PM EDT - Market closed
Market Cap 22.47M
Revenue (ttm) 661,000
Net Income (ttm) -14.13M
Shares Out 1.20M
EPS (ttm) -16.48
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $14.49
Previous Close $15.05
Change ($) -0.57
Change (%) -3.75%
Day's Open 15.07
Day's Range 14.21 - 15.26
Day's Volume 23,957
52-Week Range 11.00 - 890.58

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NEWTOWN, Pa., April 15, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announ...

4 weeks ago - GlobeNewsWire

NEWTOWN, Pa., April 07, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announ...

1 month ago - GlobeNewsWire

First and only tongue-delivered neuromodulation therapy provides new treatment option for U.S. patients living with gait deficit due to symptoms from multiple sclerosis First and only tongue-delivered n...

1 month ago - GlobeNewsWire

NEWTOWN, Pa., March 17, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announ...

1 month ago - GlobeNewsWire

NEWTOWN, Pa., March 17, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announ...

1 month ago - GlobeNewsWire

NEWTOWN, Pa., March 10, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today report...

2 months ago - GlobeNewsWire

NEWTOWN, Pa., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announc...

3 months ago - GlobeNewsWire

NEWTOWN, Pa., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, announced tod...

3 months ago - GlobeNewsWire

NEWTOWN, Pa., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today provide...

3 months ago - GlobeNewsWire

The Company's Stock Will Continue to be Listed and Traded on The Nasdaq Stock Market

3 months ago - GlobeNewsWire

NEWTOWN, Pa., Jan. 15, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announc...

3 months ago - GlobeNewsWire

Submits formal response to the U.S. Food and Drug Administration's request for additional information Submits formal response to the U.S. Food and Drug Administration's request for additional information

4 months ago - GlobeNewsWire

NEWTOWN, Pa., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, is issuing th...

4 months ago - GlobeNewsWire

NEWTOWN, Pa., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announc...

4 months ago - GlobeNewsWire

NEWTOWN, Pa., Dec. 31, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, announced tod...

4 months ago - GlobeNewsWire

Helius Medical Technologies' (HSDT) Management on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

NEWTOWN, Pa., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announc...

6 months ago - GlobeNewsWire

New clinics increase access to PoNS Treatment in population-dense areas across Canada New clinics increase access to PoNS Treatment in population-dense areas across Canada

6 months ago - GlobeNewsWire

NEWTOWN, Pa., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announc...

6 months ago - GlobeNewsWire

NEWTOWN, Pa., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, announced tod...

6 months ago - GlobeNewsWire

NEWTOWN, Pa., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, announced tod...

6 months ago - GlobeNewsWire

NEWTOWN, Pa., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announc...

6 months ago - GlobeNewsWire

NEWTOWN, Pa., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (TSX: HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today annou...

6 months ago - GlobeNewsWire

Leading Multiple Sclerosis Experts to Inform U.S. Launch Planning and Market Access Strategies Leading Multiple Sclerosis Experts to Inform U.S. Launch Planning and Market Access Strategies

7 months ago - GlobeNewsWire

NEWTOWN, Pa., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today anno...

8 months ago - GlobeNewsWire

NEWTOWN, Pa., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today annou...

8 months ago - GlobeNewsWire

NEWTOWN, Pa., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today annou...

8 months ago - GlobeNewsWire

Helius Medical Technologies, Inc. (HSDT) CEO Phil Deschamps on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Helius Medical Technologies, Inc. (HSDT) delivered earnings and revenue surprises of 33.33% and 33.00%, respectively, for the quarter ended June 2020.

9 months ago - Zacks Investment Research

NEWTOWN, Pa., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today repor...

9 months ago - GlobeNewsWire

NEWTOWN, Pa., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today annou...

9 months ago - GlobeNewsWire

Helius Medical Technologies, Inc. (HSDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

9 months ago - Zacks Investment Research

NEWTOWN, Pa., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today annou...

9 months ago - GlobeNewsWire

NEWTOWN, Pa., July 14, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), announced the dismissal of a putative shareholder class action in...

9 months ago - GlobeNewsWire

NEWTOWN, Pa., May 12, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announ...

1 year ago - GlobeNewsWire

Helius Medical Technologies, Inc. (HSDT) CEO Phil Deschamps on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

122 Subject, Multicenter, Double-Blind, Randomized, Clinical Trial Finds PoNS Treatment™ Provides Significant Improvement in Balance and Gait Deficits for Individuals Who Have Experienced a Mild-to-Mode...

1 year ago - GlobeNewsWire

122 Subject, Multicenter, Double-Blind, Randomized, Clinical Trial Finds PoNS Treatment™ found Significant Improvement in Balance and Gait Deficits for Individuals Who Have Experienced a Mild-to-Moderat...

1 year ago - GlobeNewsWire

NEWTOWN, Pa., April 22, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (TSX: HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today an...

1 year ago - GlobeNewsWire

NEWTOWN, Pa., March 24, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), today announced that its Canadian Class II license amendment app...

1 year ago - GlobeNewsWire

NEWTOWN, Pa., March 18, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, announced ...

1 year ago - GlobeNewsWire

Helius Medical Technologies, Inc. (HSDT) CEO Phil Deschamps on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Expands Access to PoNS Treatment™ in the Greater Toronto Area and Southwestern Ontario Expands Access to PoNS Treatment™ in the Greater Toronto Area and Southwestern Ontario

1 year ago - GlobeNewsWire

NEWTOWN, Pa., March 02, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today repo...

1 year ago - GlobeNewsWire

NEWTOWN, Pa., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”) CEO Philippe Deschamps has been invited to brief the US Congress o...

1 year ago - GlobeNewsWire

The Cline Medical Centre in Nanaimo is the Eighth Authorized  PoNS Treatment™ Clinic in Canada.

1 year ago - GlobeNewsWire

Eli Lilly's Acquisition Strategy, And Other News: The Good, Bad And Ugly Of Biopharma

Other stocks mentioned: LLY, DRRX
1 year ago - Seeking Alpha

NEWTOWN, Pa., Jan. 16, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), would like to clarify that the agreement between the company and ...

1 year ago - GlobeNewsWire

NEWTOWN, Pa., Jan. 16, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, announces t...

1 year ago - GlobeNewsWire

Brain Mapping Foundation and Society for Brain Mapping Therapeutics name the Portable Neuromodulation Stimulator ( PoNS™) device a trailblazing technology Brain Mapping Foundation and Society for Brain ...

1 year ago - GlobeNewsWire

About HSDT

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator (PoNS), a medical device in Canada for the treatment of chronic balance deficit due to mild-to-moderate traumatic brain injury. Its PoNS device treats neurostimulation of cranial nerves via the tongue to restore lost function. The company is headquartered in Newtown, Pennsylvania.

Industry
Medical Devices
CEO
Philippe Deschamps
Employees
19
Stock Exchange
NASDAQ
Ticker Symbol
HSDT
Full Company Profile

Financial Performance

In 2020, HSDT's revenue was $661,000, a decrease of -55.82% compared to the previous year's $1.50 million. Losses were -$14.13 million, 44.5% more than in 2019.

Financial Statements